BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AN2728: Preliminary Phase IIa data

Preliminary data from a double-blind, Australian Phase IIa trial in 46 patients with mild to moderate atopic dermatitis showed that topical, twice-daily 2% AN2728 and twice-daily 1% AN2898 for 6 weeks each met the primary endpoint of a significantly greater proportion of patient lesions showing improvement as measured by a reduction in ADSI scores at day 28 vs. vehicle-treated control lesions...

Read the full 292 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >